Pro-survival role of protein kinase C epsilon in Philadelphia chromosome positive acute leukemia

References

• Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996;88:2375–2384.
   PubMed Web of Science ®Google Scholar
• Skorski T, Bellacosa A, Nieborowska-Skorska M, et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. Embo J 1997;16:6151–6161.
   PubMed Web of Science ®Google Scholar
• Salesse S, Verfaillie CM. Mechanisms underlying abnormal trafficking and expansion of malignant progenitors in CML: BCR/ABL-induced defects in integrin function in CML. Oncogene 2002;21: 8605–8611.
   PubMed Web of Science ®Google Scholar
• Vajpai N, Strauss A, Fendrich G, et al. Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib. J Biol Chem 2008;283:18292–18302.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645–652.
   PubMed Web of Science ®Google Scholar
• Druker BJ. Imatinib mesylate in the treatment of chronic myeloid leukaemia. Expert Opin Pharmacother 2003;4:963–971.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Cortes J, O’Brien S, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002;99:3547–3553.
   PubMed Web of Science ®Google Scholar
• Guilhot F, Apperley J, Kim DW, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 2007;109:4143–4150.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006;354:2542–2551.
   PubMed Web of Science ®Google Scholar
• Li S, Li D. Stem cell and kinase activity-independent pathway in resistance of leukaemia to BCR-ABL kinase inhibitors. J Cell Mol Med 2007;11:1251–1262.
   PubMed Web of Science ®Google Scholar
• Akita Y. Protein kinase C-epsilon (PKC-epsilon): its unique structure and function. J Biochem (Tokyo) 2002;132:847–852.
   PubMed Web of Science ®Google Scholar
• Sharif TR, Sharif M. Overexpression of protein kinase C epsilon in astroglial brain tumor derived cell lines and primary tumor samples. Int J Oncol 1999;15:237–243.
   PubMed Web of Science ®Google Scholar
• Bae KM, Wang H, Jiang G, et al. Protein kinase C epsilon is overexpressed in primary human non-small cell lung cancers and functionally required for proliferation of non-small cell lung cancer cells in a p21/Cip1-dependent manner. Cancer Res 2007; 67:6053–6063.
   PubMed Web of Science ®Google Scholar
• Ding L, Wang H, Lang W, et al. Protein kinase C-epsilon promotes survival of lung cancer cells by suppressing apoptosis through dysregulation of the mitochondrial caspase pathway. J Biol Chem 2002;277:35305–35313.
   PubMed Web of Science ®Google Scholar
• Greenbaum D, Colangelo C, Williams K, et al. Comparing protein abundance and mRNA expression levels on a genomic scale. Genome Biol 2003;4:117.
   PubMed Web of Science ®Google Scholar
• Mirandola P, Gobbi G, Ponti C, et al. PKCepsilon controls protection against TRAIL in erythroid progenitors. Blood 2006;107: 508–513.
   PubMed Web of Science ®Google Scholar
• Wu SF, Huang Y, Hou JK, et al. The downregulation of onzin expression by PKCepsilon-ERK2 signaling and its potential role in AML cell differentiation. Leukemia 2010;24:544–551.
   PubMed Web of Science ®Google Scholar
• Lu D, Huang J, Basu A. Protein kinase C-epsilon activates protein kinase B/AKT via DNA-PK to protect against TNF-induced cell death. J Biol Chem 2006; 281:22799–22807.
   Google Scholar
• Slupsky JR, Kamiguti AS, Harris RJ, et al. Central role of protein kinase C epsilon in constitutive activation of ERK1/2 and Rac1 in the malignant cells of hairy cell leukemia. Am J Pathol 2007;170:745–754.
   PubMed Web of Science ®Google Scholar
• Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000;96:1070–1079.
   PubMed Web of Science ®Google Scholar
• Brandman R, Disatnik MH, Churchill E, et al. Peptides derived from the C2 domain of protein kinase C epsilon (epsilon PKC) modulate epsilon PKC activity and identify potential protein-protein interaction surfaces. J Biol Chem 2007;282:4113–4123.
   PubMed Web of Science ®Google Scholar
• Gobbi G, Masselli E, Micheloni C, et al. Hypoxia-induced down-modulation of PKCepsilon promotes trail-mediated apoptosis of tumor cells. Int J Oncol 2010;37:719–729.
   PubMed Web of Science ®Google Scholar
• Shinohara H, Kayagaki N, Yagita H, et al. A protective role of PKCepsilon against TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in glioma cells. Biochem Biophys Res Commun 2001;284:1162–1167.
   PubMed Web of Science ®Google Scholar
• Tipping AJ, Deininger MW, Goldman JM, et al. Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate. Exp Hematol 2003;31:1073–1080.
   PubMed Web of Science ®Google Scholar
• Hu M, Liu Y, Deng C, et al. Enhanced invasiveness in multidrug resistant leukemic cells is associated with overexpression of P-glycoprotein and cellular inhibitor of apoptosis protein. Leuk Lymphoma 2011;52:1302–1311.
   PubMed Web of Science ®Google Scholar
• Pardo OE, Wellbrock C, Khanzada UK, et al. FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2. Embo J 2006;25:3078–3088.
   PubMed Web of Science ®Google Scholar
• Basu A, Cline JS. Oncogenic transformation alters cisplatin-induced apoptosis in rat embryo fibroblasts. Int J Cancer 1995;63: 597–603.
   PubMed Web of Science ®Google Scholar
• Okhrimenko H, Lu W, Xiang C, et al. Protein kinase C-epsilon regulates the apoptosis and survival of glioma cells. Cancer Res 2005;65:7301–7309.
   PubMed Web of Science ®Google Scholar
• Sarveswaran S, Thamilselvan V, Brodie C, et al. Inhibition of 5-lipoxygenase triggers apoptosis in prostate cancer cells via down-regulation of protein kinase C-epsilon. Biochim Biophys Acta 2011;1813:2108–2117.
   PubMed Web of Science ®Google Scholar
• Vogel C, Marcotte EM. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet 2012;13:227–232.
   PubMed Web of Science ®Google Scholar
• Sivaprasad U, Shankar E, Basu A. Downregulation of Bid is associated with PKCepsilon-mediated TRAIL resistance. Cell Death Differ 2007;14:851–860.
   PubMed Web of Science ®Google Scholar
• Kawauchi K, Ogasawara T, Yasuyama M, et al. Involvement of Akt kinase in the action of STI571 on chronic myelogenous leukemia cells. Blood Cells Mol Dis 2003;31:11–17.
   PubMed Web of Science ®Google Scholar
• Guo B, Rothstein TL. A novel Lyn-protein kinase Cdelta/ epsilon-protein kinase D axis is activated in B cells by signalosome-independent alternate pathway BCR signaling. Eur J Immunol 2013; 43:1643–1650.
   PubMed Web of Science ®Google Scholar
• Wu J, Meng F, Kong LY, et al. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. J Natl Cancer Inst 2008;100:926–939.
   PubMed Web of Science ®Google Scholar
• Aziz MH, Hafeez BB, Sand JM, et al. Protein kinase Cvarepsilon mediates Stat3Ser727 phosphorylation, Stat3-regulated gene expression, and cell invasion in various human cancer cell lines through integration with MAPK cascade (RAF-1, MEK1/2, and ERK1/2). Oncogene 2010;29:3100–3109.
   PubMed Web of Science ®Google Scholar
• Nair RR, Tolentino JH, Hazlehurst LA. Role of STAT3 in transformation and drug resistance in CML. Front Oncol 2012; 2:30.
   PubMedGoogle Scholar
• Bewry NN, Nair RR, Emmons MF, et al. Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Mol Cancer Ther 2008;7:3169–3175.
   PubMed Web of Science ®Google Scholar
• Kang JW, Park YS, Lee DH, et al. Intracellular interaction of interleukin (IL)-32alpha with protein kinase C epsilon (PKCepsilon) and STAT3 protein augments IL-6 production in THP-1 promonocytic cells. J Biol Chem 2012;287:35556–35564.
   PubMed Web of Science ®Google Scholar
• Carpenter RL, Lo HW. STAT3 target genes relevant to human cancers. Cancers (Basel) 2014;6:897–925.
   PubMed Web of Science ®Google Scholar
• Ivaska J, Bosca L, Parker PJ. PKCepsilon is a permissive link in integrin-dependent IFN-gamma signalling that facilitates JAK phosphorylation of STAT1. Nat Cell Biol 2003;5:363–369.
   PubMed Web of Science ®Google Scholar
• Zheng B, Chambers TC, Raynor RL, et al. Human leukemia K562 cell mutant (K562/OA200) selected for resistance to okadaic acid (protein phosphatase inhibitor) lacks protein kinase C-epsilon, exhibits multidrug resistance phenotype, and expresses drug pump P-glycoprotein. J Biol Chem 1994;269:12332–12338.
   PubMed Web of Science ®Google Scholar
• Neviani P, Harb JG, Oaks JJ, et al. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest 2013;123:4144–4157.
   PubMed Web of Science ®Google Scholar